Bruce Booth

In this discussion, venture capitalist Bruce Booth, a partner at Atlas Venture, shares insights from his annual biotech year-in-review report. He argues that the biotech sector may be rebounding, pointing to recent stock performances and clinical innovations. Booth discusses the potential surge in IPOs for 2026 but cautions about the risks of poor-quality companies going public. He also analyzes the effects of DTC offerings by Eli Lilly and Novo Nordisk, which could lead employers to cut funding for weight-loss drugs. Finally, he highlights the changing dynamics in venture capital as AI draws investment away from biotech.